Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 2/2014

01-02-2014 | Research Article

CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion

Authors: Mo Zhai, Lin Cong, Yaxin Han, Guanjun Tu

Published in: Tumor Biology | Issue 2/2014

Login to get access

Abstract

Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a newly characterized oncoprotein involved in a variety of malignant tumors. However, its expression pattern and biological functions in osteosarcoma remain unclear. In the present study, CIP2A expression was analyzed in 51 human osteosarcoma specimens using immunohistochemistry. CIP2A siRNA was used in the MG-63 cell line, and the effect of CIP2A depletion on cell proliferation and invasion was evaluated. We found that CIP2A was overexpressed in 76.5 % (39/51) of osteosarcoma tissues, while normal bone tissues showed negative CIP2A expression. In addition, the positive rate of CIP2A expression was higher in stage IIB osteosarcoma than stage IIA cases. Knockdown of the CIP2A expression significantly reduced osteosarcoma cell proliferation and invasion, with decreased c-Myc expression and p-AKT expression. CIP2A depletion also facilitated apoptosis and inhibited MMP9 mRNA expression. Taken together, our data identified CIP2A as a critical oncoprotein involved in cell proliferation and invasion, which could serve as a therapeutic target in osteosarcoma.
Literature
1.
2.
Heare T, Hensley MA, Dell’Orfano S. Bone tumors: osteosarcoma and Ewing’s sarcoma. Curr Opin Pediatr. 2009;21:365–72.PubMedCrossRef
3.
Levings PP, McGarry SV, Currie TP, Nickerson DM, et al. Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma. Cancer Res. 2009;69:5648–55.PubMedCentralPubMedCrossRef
4.
Fujiwara M, Kashima TG, Kunita A, Kii I, et al. Stable knockdown of S100A4 suppresses cell migration and metastasis of osteosarcoma. Tumour Biol. 2011;32:611–22.PubMedCrossRef
5.
Hua Y, Jia X, Sun M, Zheng L, et al. Plasma membrane proteomic analysis of human osteosarcoma and osteoblastic cells: revealing NDRG1 as a marker for osteosarcoma. Tumour Biol. 2011;32:1013–21.PubMedCrossRef
6.
Sharili AS, Allen S, Smith K, Hargreaves J, et al. Expression of Snail2 in long bone osteosarcomas correlates with tumour malignancy. Tumour Biol. 2012;32:515–26.CrossRef
7.
Soo Hoo L, Zhang JY, Chan EK. Cloning and characterization of a novel 90 kDa “companion” auto-antigen of p62 overexpressed in cancer. Oncogene. 2002;21:5006–15.PubMedCrossRef
8.
Junttila MR, Puustinen P, Niemela M, Ahola R, et al. CIP2A inhibits PP2A in human malignancies. Cell. 2007;130:51–62.PubMedCrossRef
9.
Basile JR, Czerninski R. The role of CIP2A in oral squamous cell carcinoma. Canc Biol Ther. 2010;10:700–2.CrossRef
10.
Bockelman C, Koskensalo S, Hagstrom J, Lundin M, et al. CIP2A overexpression is associated with c-Myc expression in colorectal cancer. Cancer Biol Ther. 2010;13:289–95.CrossRef
11.
Bockelman C, Lassus H, Hemmes A, Leminen A, et al. Prognostic role of CIP2A expression in serous ovarian cancer. Br J Canc. 2011;105:989–95.CrossRef
12.
Dong QZ, Wang Y, Dong XJ, Li ZX, et al. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol. 2011;18:857–65.PubMedCrossRef
13.
Huang LP, Adelson ME, Mordechai E, Trama JP. CIP2A expression is elevated in cervical cancer. Cancer Biomark. 2011;8:309–17.
14.
Katz J, Jakymiw A, Ducksworth MK, Stewart CM, et al. CIP2A expression and localization in oral carcinoma and dysplasia. Canc Biol Ther. 2010;10:694–9.CrossRef
15.
Qu W, Li W, Wei L, Xing L, et al. CIP2A is overexpressed in esophageal squamous cell carcinoma. Med Oncol. 2012;29:113–8.PubMedCrossRef
16.
Ren J, Li W, Yan L, Jiao W, et al. Expression of CIP2A in renal cell carcinomas correlates with tumour invasion, metastasis and patients’ survival. Br J Canc. 2011;105:1905–11.CrossRef
17.
Teng HW, Yang SH, Lin JK, Chen WS, et al. CIP2A is a predictor of poor prognosis in colon cancer. J Gastrointest Surg. 2012;16:1037–47.PubMedCrossRef
18.
Vaarala MH, Vaisanen MR, Ristimaki A. CIP2A expression is increased in prostate cancer. J Exp Clin Canc Res. 2010;29:136.CrossRef
19.
Li W, Ge Z, Liu C, Liu Z, et al. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res. 2008;14:3722–8.PubMedCrossRef
20.
Come C, Laine A, Chanrion M, Edgren H, et al. CIP2A is associated with human breast cancer aggressivity. Clin Canc Res. 2009;15:5092–100.CrossRef
21.
Fang Y, Li Z, Wang X, Zhang S. CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis. Tumour Biol. 2012;33:2299–306.PubMedCrossRef
22.
Ren J, Li W, Yan L, Jiao W, et al. Expression of CIP2A in renal cell carcinomas correlates with tumour invasion, metastasis and patients’ survival. Br J Cancer. 2011;105:1905–11.PubMedCentralPubMedCrossRef
23.
Lee J, Park EJ, Hwang JW, Oh JM, et al. CIP2A expression is associated with synovial hyperplasia and invasive function of fibroblast-like synoviocytes in rheumatoid arthritis. Rheumatol Int. 2012;32:2023–30.PubMedCrossRef
24.
Chen KF, Liu CY, Lin YC, Yu HC, et al. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene. 2010;29:6257–66.PubMedCrossRef
25.
Lin YC, Chen KC, Chen CC, Cheng AL, et al. CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells. Oral Oncol. 2012;48:585–93.PubMedCrossRef
26.
Wang L, Gu F, Ma N, Zhang L, et al. CIP2A expression is associated with altered expression of epithelial-mesenchymal transition markers and predictive of poor prognosis in pancreatic ductal adenocarcinoma. Tumour Biol. 2013;34:2309–13.PubMedCrossRef
27.
Gordan JD, Bertout JA, Hu CJ, Diehl JA, et al. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell. 2007;11:335–47.PubMedCentralPubMedCrossRef
28.
Laurenti E, Varnum-Finney B, Wilson A, Ferrero I, et al. Hematopoietic stem cell function and survival depend on c-Myc and N-Myc activity. Cell Stem Cell. 2008;3:611–24.PubMedCentralPubMedCrossRef
29.
Hu S, Xu-Monette ZY, Tzankov A, Green T, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;121:4021–31.PubMedCrossRef
30.
Chuan YC, Iglesias-Gato D, Fernandez-Perez L, Cedazo-Minguez A, et al. Ezrin mediates c-Myc actions in prostate cancer cell invasion. Oncogene. 2010;29:1531–42.PubMedCrossRef
31.
Cho KB, Cho MK, Lee WY, Kang KW. Overexpression of c-myc induces epithelial mesenchymal transition in mammary epithelial cells. Cancer Lett. 2010;293:230–9.PubMedCrossRef
32.
Baudino TA, McKay C, Pendeville-Samain H, Nilsson JA, et al. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev. 2002;16:2530–43.PubMedCrossRef
33.
Robanus-Maandag EC, Bosch CA, Kristel PM, Hart AA, et al. Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas. J Pathol. 2003;201:75–82.PubMedCrossRef
34.
Liu Y, Chen LH, Yuan YW, Li QS, et al. Activation of AKT is associated with metastasis of nasopharyngeal carcinoma. Tumor Biol. 2012;33:241–5.CrossRef
35.
Wang X, Deng Y, Mao Z, Ma X, et al. CCN1 promotes tumorigenicity through Rac1/Akt/NF-kappaB signaling pathway in pancreatic cancer. Tumour Biol. 2012;33:1745–58.PubMedCrossRef
36.
Chen JS, Wang Q, Fu XH, Huang XH, et al. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: association with MMP-9. Hepatol Res. 2009;39:177–86.PubMedCrossRef
37.
Kaomongkolgit R, Cheepsunthorn P, Pavasant P, Sanchavanakit N. Iron increases MMP-9 expression through activation of AP-1 via ERK/Akt pathway in human head and neck squamous carcinoma cells. Oral Oncol. 2008;44:587–94.PubMedCrossRef
38.
Diaz-Montero CM, Wygant JN, McIntyre BW. PI3-K/Akt-mediated anoikis resistance of human osteosarcoma cells requires Src activation. Eur J Cancer. 2006;42:1491–500.PubMedCrossRef
39.
Miwa S, Sugimoto N, Shirai T, Hayashi K, et al. Caffeine activates tumor suppressor PTEN in sarcoma cells. Int J Oncol. 2011;39:465–72.PubMed
40.
Cenni V, Maraldi NM, Ruggeri A, Secchiero P, et al. Sensitization of multidrug resistant human osteosarcoma cells to Apo2 Ligand/TRAIL-induced apoptosis by inhibition of the Akt/PKB kinase. Int J Oncol. 2004;25:1599–608.PubMed
41.
Inoue R, Matsuki NA, Jing G, Kanematsu T, et al. The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K-Akt-NFkappaB pathway in osteosarcoma cells. Br J Pharmacol. 2005;146:633–41.PubMedCrossRef
Metadata
Title
CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion
Authors
Mo Zhai
Lin Cong
Yaxin Han
Guanjun Tu
Publication date
01-02-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1150-z

Other articles of this Issue 2/2014

Tumor Biology 2/2014 Go to the issue

Research Article

Rhomboid family gene expression profiling in breast normal tissue and tumor samples

Research Article

ILEI drives epithelial to mesenchymal transition and metastatic progression in the lung cancer cell line A549

Erratum

Erratum to: Prognostication of OCT4 isoform expression in prostate cancer

Research Article

Associations between vascular endothelial growth factor polymorphisms and prostate cancer risk: a meta-analysis

Research Article

Quantitative assessment of the influence of tumor necrosis factor alpha polymorphism with gastritis and gastric cancer risk

Research Article

Smoking and hOGG1 Ser326Cys polymorphism contribute to lung cancer risk: evidence from a meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits